Infobird Co. Ltd. (NASDAQ: IFBD), a leading provider of AI-powered customer engagement solutions in China, is now providing services to a leading global pharmaceutical and vaccine manufacturer’s subsidiary. According to the announcement, Infobird will be utilizing its AI chatbots and impressive experience in the healthcare industry to support the client’s digital and intelligent customer-engagement initiative, including its patient notification process regarding COVID-19, HPV and other childhood vaccines. The new client is one of the world’s leading professional human-vaccine development and production companies and is committed to producing high-quality, safe vaccines. The partnership will use Infobird’s AI chatbot SaaS product to enable the vaccine manufacturer to offer its customers with professional, attentive and convenient vaccination notification services. “Under this cooperation, Infobird’s intelligent outbound call solution primarily includes AI Chatbot outbound call, which will be responsible for the client’s vaccination notification, such as COVID-19 vaccine, HPV vaccine and various childhood vaccines,” the announcement states. “The entire process is operated by AI without human involvement, which can help to reduce the staff’s burden while improving customer experience and helping the client to increase the vaccination rate. At the same time, since vaccines are one of the most effective measures to prevent and control the COVID-19 epidemic at present, utilizing Infobird’s intelligent outbound call method is expected to help the client to notify users of the second and third doses of COVID-19 vaccine in advance, which is expected to largely increase the number of COVID-19 vaccinations for the client.”
To view the full press release, visit https://ibn.fm/dFJCi
About Infobird Software Co. Ltd.
Infobird, headquartered in Beijing, China, is a software-as-a-service provider of innovative AI-powered or enabled customer-engagement solutions in China. For more information about the company, visit www.Infobird.com.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
